Journal of Cardiovascular Pharmacology and Therapeutics最新文献

{"title":"From Indirect Evidence to Head-to-Head Trials in Anticoagulation: Clinical Implications of the COBRRA Moment in DOAC Treatment.","authors":"Andrej Belancic, Josip Andelo Borovac","doi":"10.1177/10742484261440329","DOIUrl":"https://doi.org/10.1177/10742484261440329","url":null,"abstract":"","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261440329"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alterations of Platelet MicroRNAs Associated With Dapagliflozin Treatment in Individuals With Type 2 Diabetes Mellitus.","authors":"Feng Chen, Xueyan Ding, Feifei Dong, Xinghua Shan, Chao Liu, Rongbing Peng, Lina Liu, Yangyong Sun, Manli Yu","doi":"10.1177/10742484261452727","DOIUrl":"10.1177/10742484261452727","url":null,"abstract":"<p><p>BackgroundPlatelet hyperactivity contributes to elevated cardiovascular risk in type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors, including dapagliflozin, exert beneficial effects on platelet function and cardiovascular outcomes. As platelet microRNAs (miRNAs) are established during megakaryopoiesis, we aimed to characterize the platelet miRNA expression in T2DM and after dapagliflozin treatment.MethodsPlatelet miRNA profiles were compared between T2DM patients and controls using microarray, with qRT-PCR validation in an independent cohort (25 T2DM and 19 controls). T2DM patients were re-evaluated after 3-month dapagliflozin treatment.ResultsExploratory microarray identified 602 candidate miRNAs with >2-fold differences between T2DM and control pools. qRT-PCR confirmed significant changes in miR-15b-3p, miR-146a-5p, miR-155-5p, and miR-223-3p (all <i>q</i> < 0.05), as well as nominally significant changes in miR-21-5p and miR-320a (both <i>q</i> = 0.052). In T2DM, miR-320a negatively correlated with mean platelet volume, platelet distribution width, and platelet large cell ratio, whereas miR-146a-5p showed positive correlations with platelet size parameters. Additionally, miR-21-5p positively and miR-223-3p negatively associated with soluble P-selectin. In an uncontrolled pre-post analysis, platelet miR-223-3p and miR-320a levels were significantly higher after dapagliflozin treatment. In silico target prediction yielded putative enrichment in pathways related to transcriptional regulation, insulin signaling, and autophagy, which likely reflects regulatory programs established in parent megakaryocytes and warrants functional validation.ConclusionAltered levels of miR-15b-3p, miR-146a-5p, miR-155-5p, and miR-223-3p are associated with platelet activation and maturation in T2DM patients. Dapagliflozin treatment may be associated with changes in platelet levels of miR-223-3p and miR-320a, hypothetically reflecting alterations in megakaryocytic programming during therapy.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261452727"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147981917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Needle to Pill: Oral PCSK9 Inhibition Enters the Lipid-Lowering Armamentarium.","authors":"Andrej Belancic, Josip Andelo Borovac","doi":"10.1177/10742484261476920","DOIUrl":"https://doi.org/10.1177/10742484261476920","url":null,"abstract":"","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261476920"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous Canrenone in Paroxysmal Atrial Fibrillation: A Reappraisal of Clinical Utility.","authors":"Shameer Tahir","doi":"10.1177/10742484261429978","DOIUrl":"https://doi.org/10.1177/10742484261429978","url":null,"abstract":"","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261429978"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147815683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABCD-GENE Score and Bleeding in Post-PCI Patients: Implications for Guided De-Escalation of Antiplatelet Therapy.","authors":"James C Coons, Kathleen Polkowski, Linda Prebehalla, Anson Conrad Smith, Philip E Empey","doi":"10.1177/10742484261457268","DOIUrl":"10.1177/10742484261457268","url":null,"abstract":"<p><p>BackgroundThe ABCD-GENE (Age, Body Mass Index, Chronic Kidney Disease, Diabetes Mellitus, and Genotyping) score is a tool used to identify increased thrombotic risk in clopidogrel-treated patients. We evaluated the association between a low ABCD-GENE score (<10) and Bleeding Academic Research Consortium (BARC)-defined bleeding among prasugrel or ticagrelor and clopidogrel-treated patients.MethodsThis was an IRB-approved retrospective cohort study of patients who underwent percutaneous coronary intervention (PCI) and <i>CYP2C19</i> genotyping. The primary outcome was time to first bleed of any severity within 1 year. Time to first major bleed, defined by BARC 3a, 3b, 3c, or 5 criteria, and major adverse cardiovascular events (MACE) were secondary outcomes. BARC bleeding events were compared between prasugrel or ticagrelor and clopidogrel-treated patients and stratified by the ABCD-GENE score threshold of ≥10. Kaplan-Meier and multivariable Cox proportional hazards model were used for time-to-event analyses.ResultsOf 2547 patients, 1760 were in the low score group, and 787 were in the high score group. Kaplan-Meier analysis showed that any bleeding (<i>P</i> = .008) and major bleeding (<i>P</i> = .015) were less for those with a low score compared to a high score. Among those in the low score group, any bleeding (<i>P</i> < .001) and major bleeding (<i>P</i> = .022) were lower with clopidogrel versus prasugrel or ticagrelor. However, the ABCD-GENE score was not independently associated with bleeding in the Cox model. No difference in MACE was observed by treatment in the low score group.ConclusionsThe ABCD-GENE score was associated with BARC bleeding, yet other variables had a greater impact such as history of GI bleed, anticoagulation, P2Y12 inhibitor, and age. Patients with a low score who received prasugrel or ticagrelor had more bleeding versus clopidogrel. Our findings support further evaluation of the ABCD-GENE score as a tool for guided P2Y12 inhibitor de-escalation post-PCI.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261457268"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary Evidence for the Association of APOB rs1042034 With Short-Term Statin-Induced Lipid Lowering: An Exploratory Study in Vietnam.","authors":"Chau Thi Kim Doan, Anh Tan To Le, Chieu Thi Truong, Loc Duc Ngo, Tran Tran Nguyen, Duy Tran Khanh Nguyen, Phi Cong Pham, Tram Thi Bich Vo, Hao Minh Pham, Dung Thanh Nguyen, Tien Ngoc Thuy Pham, Bao The Nguyen","doi":"10.1177/10742484261428536","DOIUrl":"10.1177/10742484261428536","url":null,"abstract":"<p><p>ObjectivesTo characterize the rs1042034 allele distribution in Vietnamese adults with untreated hypercholesterolemia and evaluate its impact on baseline lipid profiles and the early lipid-lowering response to rosuvastatin 20 mg.Materials and MethodsIn this cross-sectional exploratory study, 79 adults with low-density lipoprotein cholesterol [LDL-C] ≥ 3.4 mmol/L were enrolled and treated with rosuvastatin 20 mg plus lifestyle advice for 3 months. Genotypes were determined by TaqMan real-time PCR with Sanger sequencing validation. Baseline and 3-month lipid panels (LDL-C, high-density lipoprotein cholesterol [HDL-C], total cholesterol, non-HDL-C, triglycerides) were measured. Between-group comparisons used Kruskal-Wallis/ANOVA as appropriate; analysis of covariance (ANCOVA) models adjusted for baseline values assessed genotype (TT vs. CT + CC) effects on posttreatment lipids. Multivariable linear regression examined age, sex, and body-mass index as predictors; false discovery rate correction was applied.ResultsBaseline lipid concentrations did not differ significantly by genotype (overall LDL-C 4.37 ± 0.62 mmol/L; total cholesterol 6.62 ± 0.77 mmol/L). After three months, LDL-C reductions differed markedly by genotype (<i>P</i> < .001): median absolute reductions were -0.47 mmol/L (TT; fractional -9.7%), -1.12 mmol/L (CT; -28.1%) and -1.28 mmol/L (CC; -29.8%). HDL-C change also differed (<i>P</i> = .049) with medians 0.09, 0.24 and 0.15 mmol/L for TT, CT and CC, respectively. ANCOVA (adjusting for baseline) showed the TT genotype was independently associated with higher posttreatment LDL-C (β = 0.758; <i>P</i> = .001), lower posttreatment HDL-C (β = -0.121; <i>P</i> = .004), and higher TC (β = 0.482; <i>P</i> = .026) and non-HDL-C (β = 0.566; <i>P</i> = .007); TG was not affected (<i>P</i> = .751).ConclusionsThis study provides preliminary evidence that APOB rs1042034 polymorphism significantly influences rosuvastatin efficacy in Vietnamese patients with hypercholesterolemia.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261428536"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Norepinephrine Versus Dopamine as Vasoactive Therapy in Cardiogenic Shock: Association With 28-Day Mortality in a Retrospective Cohort Study.","authors":"Suthida Chanchenchop, Supanee Sinphurmsukskul, Krittin Bunditanukul","doi":"10.1177/10742484261456161","DOIUrl":"10.1177/10742484261456161","url":null,"abstract":"<p><p>BackgroundCardiogenic shock remains a life-threatening condition with persistently high mortality. Norepinephrine and dopamine are commonly used vasoactive agents; however, comparative data on clinical outcomes remain limited.MethodsThis retrospective cohort study included 388 adults with cardiogenic shock treated with norepinephrine (<i>n</i> = 72) or dopamine (<i>n</i> = 316) at King Chulalongkorn Memorial Hospital, Thailand. The primary outcome was 28-day mortality. Survival was evaluated using Kaplan-Meier analysis and Cox proportional hazards regression. Inverse probability of treatment weighting (IPTW) was applied to adjust for confounding by indication.ResultsMortality at 28 days occurred in 30.6% and 25.9% of the norepinephrine and dopamine groups, respectively. No statistically significant difference in 28-day mortality was observed in either the unadjusted (HR 0.84, 95% CI 0.52-1.34; <i>P</i> = .463) or IPTW-adjusted Cox proportional hazards model (HR 1.10, 95% CI 0.64-1.88; <i>P</i> = .725). Epinephrine rescue rates were comparable between groups (27.7% vs 24.2%; <i>P</i> = .551). Independent predictors of 28-day mortality included age ≥65 years, cardiopulmonary resuscitation, and epinephrine use (<i>P</i> < .001 for all), as well as renal replacement therapy and endotracheal intubation (<i>P</i> = .003 for both).ConclusionThe present study did not demonstrate a significant difference in 28-day mortality between norepinephrine and dopamine; however, dopamine was associated with a significantly higher incidence of arrhythmias.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261456161"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148251792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bringing <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> (JCPT) to a Next Level: Strategies and Vision to Ensure a Sustained Journal Growth.","authors":"Josip Andelo Borovac","doi":"10.1177/10742484261436224","DOIUrl":"https://doi.org/10.1177/10742484261436224","url":null,"abstract":"","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261436224"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147498757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study.","authors":"Yohei Funauchi, Toru Takase, Kazuyoshi Kakehi, Masafumi Ueno, Gaku Nakazawa","doi":"10.1177/10742484261459258","DOIUrl":"10.1177/10742484261459258","url":null,"abstract":"<p><p>BackgroundVericiguat improves outcomes in heart failure with reduced ejection fraction (HFrEF), but its vascular and hemodynamic effects remain unclear. We explored changes in flow-mediated dilation (FMD) and invasive hemodynamics after vericiguat in symptomatic patients with HFrEF receiving guideline-directed medical therapy (GDMT).MethodsIn this single-center, open-label, single-arm exploratory pilot study, 10 patients with symptomatic HFrEF underwent assessment of FMD, right heart catheterization at rest and during 20-W supine exercise, echocardiography, laboratory testing, and 6-min walk distance (6MWD) before and after vericiguat. Vericiguat was uptitrated to 10 mg/day where tolerated.ResultsAfter treatment, FMD increased from 4.7 (3.0-6.1) to 6.9 (5.5-7.6)% (<i>P</i> = .015), GLS improved from -6.8 (-8.6 to -5.5) to -9.0 (-10.5 to -6.7)% (<i>P</i> = .009), resting cardiac output increased from 3.8 (3.6-5.4) to 4.6 (3.5-5.4) L/min (<i>P</i> = .047), resting systemic vascular resistance decreased from 1664.1 (1327.2-1781.2) to 1293.1 (1143.6-1623.5) dyn·s·cm^-5 (<i>P</i> = .002), and 6MWD increased from 334.0 (251.3-395.0) to 355.0 (262.5-453.8) m (<i>P</i> = .036). During 20-W exercise, cardiac output increased from 5.4 (4.6-5.9) to 6.5 (4.8-6.9) L/min (<i>P</i> = .030), whereas exercise systemic vascular resistance showed only a decreasing trend (<i>P</i> = .070).ConclusionsIn symptomatic patients with HFrEF receiving GDMT, vericiguat was associated with changes in peripheral vascular function and resting hemodynamic indices. However, exercise systemic vascular resistance did not improve significantly. These findings are exploratory and hypothesis-generating.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261459258"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to Direct Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation: A Single-Center Retrospective Study.","authors":"Cuie Chang, Sha Lv, Lingyan Yu, Lingcheng Xu, Donghang Xu, Haibin Dai, Junjun Xu","doi":"10.1177/10742484261490639","DOIUrl":"https://doi.org/10.1177/10742484261490639","url":null,"abstract":"<p><p>ObjectiveTo investigate adherence to four direct oral anticoagulants (DOACs) and its influencing factors in patients with non-valvular atrial fibrillation (NVAF), providing evidence for strategies to improve adherence.MethodsA retrospective cohort study included NVAF patients initiating DOAC therapy at a tertiary hospital (January 2016-November 2023). Adherence was evaluated using the proportion of days covered (PDC), with PDC ≥ 0.8 defined as good adherence. Adherence levels for dabigatran, rivaroxaban, apixaban, and edoxaban were compared at 3, 6, 9, and 12 months. Logistic regression identified factors influencing 1-year adherence, assessing the impact of initiation year and the National Volume-Based Drug Procurement (NVBP) policy.ResultsA total of 1,150 NVAF patients were enrolled (dabigatran: n = 401; rivaroxaban: n = 656; apixaban: n = 18; edoxaban: n = 75),In this main cohort, overall adherence progressively declined, with only 40.78% achieving PDC ≥ 0.8 at 1 year. Significant differences existed among groups (P<0.001). Dabigatran demonstrated the highest 1-year adherence (53.62%), followed by rivaroxaban (34.91%), apixaban (27.78%), and edoxaban (26.67%). Compared with dabigatran, rivaroxaban (OR=0.47) and edoxaban (OR=0.33) were independently associated with poorer adherence. Age ≥75 years (OR=0.62) and self-pay (OR=0.49) were risk factors for poor adherence, while diabetes (OR=1.48) and prior stroke (OR=1.48) predicted better adherence. Patients initiating therapy in 2017 showed the highest adherence. Post-NVBP, generic dabigatran adherence exceeded the original formulation at 6 months (P=0.038), but this difference disappeared at 1 and 2 years.ConclusionDOAC adherence among NVAF patients is suboptimal and decreases over time. Among the four DOACs, dabigatran was associated with the highest adherence. Elderly (≥75 years) and self-paying patients are at higher risk of poor adherence, whereas those with diabetes or stroke history show better adherence. The NVBP policy improves adherence short-term, but long-term effects are limited. Targeted interventions are necessary for high-risk populations.</p>","PeriodicalId":15281,"journal":{"name":"Journal of Cardiovascular Pharmacology and Therapeutics","volume":"31 ","pages":"10742484261490639"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}